Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021.

Autor:	Santomauro DF; Queensland Centre for Mental Health Research, Wacol, QLD, Australia; The University of Queensland, School of Public Health, Herston, QLD, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. Electronic address: d.santomauro@uq.edu.au., Vos T; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA., Whiteford HA; Queensland Centre for Mental Health Research, Wacol, QLD, Australia; The University of Queensland, School of Public Health, Herston, QLD, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA., Chisholm D; Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland., Saxena S; Harvard T H Chan, School of Public Health, Harvard University, Boston, MA, USA., Ferrari AJ; Queensland Centre for Mental Health Research, Wacol, QLD, Australia; The University of Queensland, School of Public Health, Herston, QLD, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Jazyk:	angličtina
Zdroj:	The lancet. Psychiatry [Lancet Psychiatry] 2024 Dec; Vol. 11 (12), pp. 1012-1021.
DOI:	10.1016/S2215-0366(24)00317-1
Abstrakt:	Background: Access to effective treatment for major depressive disorder remains limited and difficult to track across place and time. We analysed the available data on minimally adequate treatment (MAT) for major depressive disorder globally with the aim of providing a useful metric against which to monitor national responses to the growing public health burden imposed by major depressive disorder. Methods: MAT was defined as pharmacotherapy (1 month of medication, plus four visits to a medical doctor) or psychotherapy (eight visits with any professional). From existing reviews, we identified mental health surveys that assessed major depressive disorder within the general population as well as health service uptake by individuals with major depressive disorder. Data by ethnicity were not available. Estimates of MAT, antidepressant use, or use of any mental health service were extracted. The latter two estimates were adjusted to reflect likely MAT rates via a network meta-analysis. Adjusted MAT estimates were analysed via a Bayesian meta-regression using the Disease Modelling Meta-Regression (DisMod-MR 2.1) tool. This analysis estimated MAT coverage among people with major depressive disorder by age, sex, location, and year. Final MAT estimates were standardised by age and sex against the existing age and sex distribution of people with major depressive disorder globally. People with lived experience were involved in the design, preparation, interpretation, and writing of this manuscript. Findings: The analysed dataset included 145 estimates from 32 studies, covering 31 countries, 14 regions, and six super-regions. The proportion of people with major depressive disorder receiving MAT globally in 2021 was 9·1% (95% uncertainty interval 7·2-11·6), with 10·2% (8·2-13·1) of females and 7·2% (5·7-9·3) of males with major depressive disorder receiving MAT. MAT coverage was highest in high-income locations (27·0% [21·7-34·4]), with Australasia having the highest rate (29·2% [21·4-40·8]). MAT coverage was lowest in sub-Saharan Africa (2·0% [1·5-2·6]), within which western sub-Saharan Africa (1·8% [1·4-2·5]) had the lowest coverage. Seven countries (Australia, Belgium, Canada, Germany, the Netherlands, South Korea, and Sweden) were estimated to have MAT coverage exceeding 30%, while 90 countries were estimated to have coverage lower than 5%. Interpretation: Despite many gaps in the available data, estimates show that, globally, most individuals with major depressive disorder do not receive MAT. Services must improve to reach a global coverage that better meets the mental health needs of those with major depressive disorder. Urgent attention should be given to the scale-up of effective intervention strategies, especially in low-income and middle-income countries, as well as further research into better quality treatment options for major depressive disorder. We present a means by which the MAT gap for major depressive disorder can be quantified, to monitor and inform action by governments and international partners. Funding: Queensland Health and the Bill & Melinda Gates Foundation. Competing Interests: Declaration of interests SS is a senior advisor to McKinsey Health Institute. All other authors declare no competing interests. (Copyright © 2024 World Health Organization. Published by Elsevier Ltd. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu